Deborah Fallon
Family · Cameron Park, CANPI 1639243561
Payments from drug & device makers
Across 992 payments — averaging $25.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$4K
- Johnson & Johnson$3K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$3K
- Otsuka America Pharmaceutical, Inc.$3K
- Teva Pharmaceuticals USA, Inc.$2K
- Neurocrine Biosciences, Inc.$2K
- plus $8K from 19 others
What the payments were for
- Food & beverage$24,80299%
- Education$1291%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 132 | $3,521 |
| Johnson & Johnson | 67 | $3,299 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 203 | $3,180 |
| Otsuka America Pharmaceutical, Inc. | 99 | $2,844 |
| Teva Pharmaceuticals USA, Inc. | 104 | $2,348 |
| Neurocrine Biosciences, Inc. | 53 | $2,111 |
| Sunovion Pharmaceuticals Inc. | 119 | $1,962 |
| Alkermes, Inc. | 41 | $1,417 |
| Lundbeck LLC | 47 | $991 |
| Vanda Pharmaceuticals Inc. | 34 | $884 |
| Takeda Pharmaceuticals U.S.A., Inc. | 22 | $502 |
| Axsome Therapeutics, Inc. | 8 | $356 |
| Bausch Health US, LLC | 18 | $344 |
| E.r. Squibb & Sons, L.L.C. | 8 | $341 |
| Almatica Pharma LLC | 13 | $186 |
| Epizyme, Inc. | 1 | $124 |
| Merck | 4 | $89 |
| Indivior Inc. | 4 | $85 |
| Eisai Inc. | 4 | $85 |
| Boehringer Ingelheim | 1 | $77 |
| Supernus Pharmaceuticals, Inc. | 3 | $47 |
| Idorsia Pharmaceuticals US Inc | 2 | $42 |
| Avanir Pharmaceuticals, Inc. | 2 | $40 |
| Luye Pharma (USA) Ltd. | 2 | $36 |
| Alfasigma USA, Inc. | 1 | $22 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- LYBALVI$1,356
- SPRAVATO$1,004
- INVEGA SUSTENNA$979
- ABILIFY MAINTENA$838
- INGREZZA$777
- VRAYLAR$565
- ABILIFY ASIMTUFII$491
- REXULTI$487
- UZEDY$464
- ARISTADA$445
- CAPLYTA$355
- Austedo XR$245
- Fanapt$242
- COBENFY$227
- AUSTEDO$226
- Auvelity$215
- INVEGA TRINZA$126
- TAZVERIK$124
- ARISTADA INITIO$111
How this compares
$24,931 in reported general payments places this provider in the 95th percentile of 10,634 family providers in California.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RexultiBrexpiprazole | 121 | $192,376 |
| VraylarCariprazine Hcl | 101 | $166,171 |
| Invega TrinzaPaliperidone Palmitate | 18 | $159,572 |
| Invega SustennaPaliperidone Palmitate | 54 | $152,721 |
| Austedo XrDeutetrabenazine | 14 | $105,296 |
| CaplytaLumateperone Tosylate | 43 | $77,071 |
| SpravatoEsketamine Hcl | 24 | $57,103 |
| Lurasidone Hcl | 123 | $46,089 |
| ZyprexaOlanzapine | 13 | $34,244 |
| TrintellixVortioxetine Hydrobromide | 29 | $20,144 |
| Aripiprazole | 103 | $15,910 |
| BelsomraSuvorexant | 36 | $15,474 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 64 | $9,107 |
| Zyprexa ZydisOlanzapine | 11 | $7,818 |
| Quetiapine Fumarate | 250 | $7,236 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Johnson & JohnsonInvega Trinza, Invega Sustenna, Spravato | $3,299 | $369,39796 claims |
| Otsuka America Pharmaceutical, Inc.Rexulti | $2,844 | $192,376121 claims |
| AbbVieVraylar | $3,521 | $166,171101 claims |
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $2,348 | $105,29614 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $3,180 | $77,07143 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $502 | $20,14429 claims |
| MerckBelsomra | $89 | $15,47436 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,634 family providers in California.
Other family in Cameron Park
- Lori RobertsonChino Hills$475K
- Annette ShonLos Angeles$406K
- Nancy GardettoSan Diego$394K
- Lisa HigginsHanford$311K
- Jennifer TougasBakersfield$302K
- Kim SchaferSacramento$288K
- Dawn MeyerSan Diego$270K
- Jennifer KangCerritos$255K
- Jenine StoneEscondido$231K
- Erin DwyerSan Diego$189K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.